Frequent subversion of the PI3K (phosphoinositide 3-kinase) pathway during neoplastic transformation contributes to several hallmarks of cancer that result in a competitive advantage for cancer cells. Deregulation of this pathway can be the result of genomic alterations such as PIK3CA mutation, PTEN (phosphatase and tensin homologue deleted on chromosome 10) loss or the activation of upstream protein tyrosine kinases. Not surprisingly, the PI3K signalling pathway has become an attractive therapeutic target, and numerous inhibitors are in clinical trials. Unfortunately, current therapies for advanced cancers that target PI3K often lead to the development of resistance and relapse of the disease. It is therefore important to establish the molecular mechanisms of resistance to PI3K-targeted therapy. With the focus on breast cancer, in the present article, we summarize the different ways of targeting PI3K, review potential mechanisms of resistance to PI3K inhibition and discuss the rationale of combination treatments to reach a balance between efficacy and toxicity.
Skip Nav Destination
Article navigation
August 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
August 11 2014
Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine
Cedric Leroy;
Cedric Leroy
1
*Friedrich Miescher Institute for Biomedical Research, Mechanisms of Cancer, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
Search for other works by this author on:
Romain J. Amante;
Romain J. Amante
1
*Friedrich Miescher Institute for Biomedical Research, Mechanisms of Cancer, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
Search for other works by this author on:
Mohamed Bentires-Alj
Mohamed Bentires-Alj
2
*Friedrich Miescher Institute for Biomedical Research, Mechanisms of Cancer, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
2To whom correspondence should be addressed (emailbentires@fmi.ch).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
January 23 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (4): 733–741.
Article history
Received:
January 23 2014
Citation
Cedric Leroy, Romain J. Amante, Mohamed Bentires-Alj; Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine. Biochem Soc Trans 1 August 2014; 42 (4): 733–741. doi: https://doi.org/10.1042/BST20140034
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.